ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1485

Efficacy of Yttrium-90 Radiosynovectomy in Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome

Sulaiman M Al-Mayouf1, Nora AlMutairi2 and Khalid Alismail3, 1Pediatric Rheumatology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, 2Pedaitric Rheumatology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, 3Musculoskeletal Radiology, King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Synovectomy

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects Posters. Juvenile Arthritis and Miscellaneous Rheumatic Diseases

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Camptodactyly-arthropathy-coxa-vara-pericarditis (CACP) syndrome is an autosomal recessive disorder caused by mutations in PRG4 gene that encodes for proteoglycan 4, the main lubricant for joints and tendon surfaces. It is non-inflammatory arthropathy, characterized by joint effusions and synovial hypertrophy. So far, there is no effective treatment for this disorder. We evaluated the effectiveness of yttrium-90 radiosynovectomy in arthropathy of patients with CACP syndrome

Methods:

Consecutive patients with CACP syndrome prospectively evaluated at the enrollment and 3 months after the right knee injection with yttrium-90. The outcome variables were patient/ parent and physician’s global assessment measured by a 3-point scale, right knee swelling and range of motion on a 3-point scale, in addition to Magnetic Resonance Imaging(MRI) assessment of the right knee for bone, cartilage, fluid, synovial hypertrophy and soft tissue changes.

Results:

Six (3 boys, 3 girls) patients with mean age of 12 years and mean follow-up duration of 8.5 years completed a single right knee intra-articular yttrium-90 injection with 5 mCi. The procedure was well tolerated without adverse events apart from mild and transient joint pain in 2 patients. There was a minimal radioisotope leakage to soft tissue in 2 patients. During the 3 months follow-up interval, there was no improvement in the outcome variables. Patients and parents did not notice favorable therapeutic effects and global physician assessment was unsatisfactory. No difference in knee joint swelling or range of motion. Furthermore, MRI findings were unchanged. However, there was minimal increase in synovial fluid post injection.

Conclusion:

Yttrium-90 radiosynovectomy seems to be safe and well tolerated procedure, but with the given dose and interval time it didn’t show a beneficial therapeutic effect in arthropathy of CACP syndrome.


Disclosure: S. M. Al-Mayouf, None; N. AlMutairi, None; K. Alismail, None.

To cite this abstract in AMA style:

Al-Mayouf SM, AlMutairi N, Alismail K. Efficacy of Yttrium-90 Radiosynovectomy in Camptodactyly-Arthropathy-Coxa Vara-Pericarditis Syndrome [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/efficacy-of-yttrium-90-radiosynovectomy-in-camptodactyly-arthropathy-coxa-vara-pericarditis-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/efficacy-of-yttrium-90-radiosynovectomy-in-camptodactyly-arthropathy-coxa-vara-pericarditis-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology